vs
CytomX Therapeutics, Inc.（CTMX）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是CytomX Therapeutics, Inc.的1.5倍（$27.1M vs $18.7M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -120.8%，领先120.0%），Rumble Inc.同比增速更快（-10.5% vs -25.7%），CytomX Therapeutics, Inc.自由现金流更多（$-15.8M vs $-31.7M），过去两年Rumble Inc.的营收复合增速更高（15.2% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
CTMX vs RUM — 直观对比
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $27.1M |
| 净利润 | $-154.0K | $-32.7M |
| 毛利率 | — | 5.5% |
| 营业利润率 | -6.9% | -131.1% |
| 净利率 | -0.8% | -120.8% |
| 营收同比 | -25.7% | -10.5% |
| 净利润同比 | 97.6% | 86.2% |
| 每股收益（稀释后） | — | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $24.8M | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $50.9M | $23.7M | ||
| Q4 24 | $38.1M | $30.2M | ||
| Q3 24 | $33.4M | $25.1M | ||
| Q2 24 | $25.1M | $22.5M | ||
| Q1 24 | $41.5M | $17.7M |
| Q4 25 | — | $-32.7M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | $-154.0K | — | ||
| Q1 25 | $23.5M | $-2.7M | ||
| Q4 24 | $18.9M | $-236.8M | ||
| Q3 24 | $5.7M | $-31.5M | ||
| Q2 24 | $-6.5M | $-26.8M | ||
| Q1 24 | $13.8M | $-43.3M |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
| Q4 25 | — | -131.1% | ||
| Q3 25 | — | -113.6% | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | -153.5% | ||
| Q4 24 | 46.4% | -80.1% | ||
| Q3 24 | 12.3% | -131.0% | ||
| Q2 24 | -33.7% | -172.7% | ||
| Q1 24 | 28.1% | -197.4% |
| Q4 25 | — | -120.8% | ||
| Q3 25 | — | -65.7% | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 46.2% | -11.2% | ||
| Q4 24 | 49.6% | -783.2% | ||
| Q3 24 | 17.2% | -125.9% | ||
| Q2 24 | -26.0% | -119.2% | ||
| Q1 24 | 33.3% | -244.1% |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $-1.17 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $274.8M |
| 总资产 | $175.1M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $237.9M | ||
| Q3 25 | — | $269.8M | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | $301.3M | ||
| Q4 24 | $38.1M | $114.0M | ||
| Q3 24 | $40.6M | $132.0M | ||
| Q2 24 | $43.2M | $154.2M | ||
| Q1 24 | $36.2M | $183.8M |
| Q4 25 | — | $274.8M | ||
| Q3 25 | — | $302.2M | ||
| Q2 25 | $119.9M | — | ||
| Q1 25 | $25.0M | $339.6M | ||
| Q4 24 | $-456.0K | $-63.1M | ||
| Q3 24 | $-23.5M | $166.1M | ||
| Q2 24 | $-31.2M | $192.7M | ||
| Q1 24 | $-31.7M | $210.7M |
| Q4 25 | — | $336.8M | ||
| Q3 25 | — | $367.2M | ||
| Q2 25 | $175.1M | — | ||
| Q1 25 | $98.5M | $391.1M | ||
| Q4 24 | $120.5M | $195.3M | ||
| Q3 24 | $139.0M | $217.2M | ||
| Q2 24 | $159.2M | $243.2M | ||
| Q1 24 | $184.7M | $263.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $-31.7M |
| 自由现金流率自由现金流/营收 | -84.6% | -117.2% |
| 资本支出强度资本支出/营收 | 0.1% | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $-70.8M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-29.4M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.0M | $-14.5M | ||
| Q4 24 | $-19.9M | $-12.4M | ||
| Q3 24 | $-20.7M | $-19.1M | ||
| Q2 24 | $-19.5M | $-21.7M | ||
| Q1 24 | $-26.0M | $-33.9M |
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | $-14.6M | ||
| Q4 24 | $-20.0M | $-12.4M | ||
| Q3 24 | $-20.7M | $-19.9M | ||
| Q2 24 | $-19.6M | $-23.1M | ||
| Q1 24 | $-26.2M | $-34.3M |
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | -61.7% | ||
| Q4 24 | -52.5% | -40.9% | ||
| Q3 24 | -62.1% | -79.5% | ||
| Q2 24 | -78.2% | -102.8% | ||
| Q1 24 | -63.1% | -193.3% |
| Q4 25 | — | 8.5% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 3.4% | ||
| Q2 24 | 0.4% | 6.1% | ||
| Q1 24 | 0.3% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
